The Herbert Irving Comprehensive Cancer Center (HICCC) Protocol Review and Monitoring System (PRMS) is responsible for independent scientific evaluation, prioritization, and monitoring of all cancer clinical research studies conducted at Columbia University Irving Medical Center (CUIMC). The PRMS is independent of and complements the activities of the Institutional Review Boards (IRBs) and HICCC Data Safety and Monitoring Committee (DSMC). The PRMS encompasses activities of the HICCC Disease Based Teams, Feasibility Committee, and Protocol Review and Monitoring Committee (PRMC). Although independently managed, these entities maintain close interactions and collaborations.
The Specific Aims of the HICCC PRMS are the following: (1) Provide scientific review and prioritization of all applicable cancer-related clinical research protocols within the HICCC, (2) Monitor the progress of ongoing studies to ensure that accrual is sufficient to meet scientific objectives, (3) Determine whether trials should continue or close for lack of scientific progress, and (4) Assess and implement the recommendations of the Data Safety and Monitoring Committee (DSMC) regarding issues that may affect the scientific integrity of interventional trials. The process for review of cancer clinical research studies through the PRMS are as follows: ? Disease Based Teams: Assess new trials for scientific value, fit and prioritization with existing disease-based research portfolios ? Feasibility Committee: Review protocol feasibility to determine that adequate resources are in place prior to PRMC review ? PRMC: Evaluate interventional protocols for scientific merit, innovation, and statistical soundness so as to assess their priority at initial submission. The PRMC also assess the scientific and accrual progress of interventional cancer trials at the time of continuing review. In 2018, the PRMC monitored 381 active interventional studies. The PRMC reviewed 128 new studies (full board review: 96; expedited review: 32) and 448 amendments. 1

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Ghorpade, Devram S; Ozcan, Lale; Zheng, Ze et al. (2018) Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555:673-677
Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A :
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa. Am J Ophthalmol 194:120-125
Bianchetti, E; Bates, S J; Carroll, S L et al. (2018) Usp9X Regulates Cell Death in Malignant Peripheral Nerve Sheath Tumors. Sci Rep 8:17390
Shang, Enyuan; Zhang, Yiru; Shu, Chang et al. (2018) Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8:15383
Proto, Jonathan D; Doran, Amanda C; Subramanian, Manikandan et al. (2018) Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest 128:2370-2375
Apatoff, Mary Ben L; Sengillo, Jesse D; White, Eugenia C et al. (2018) Autologous stem cell therapy for inherited and acquired retinal disease. Regen Med 13:89-96
Shen, Megan Johnson; Prigerson, Holly G; Ratshikana-Moloko, Mpho et al. (2018) Illness Understanding and End-of-Life Care Communication and Preferences for Patients With Advanced Cancer in South Africa. J Glob Oncol :1-9
Connors, Thomas J; Baird, J Scott; Yopes, Margot C et al. (2018) Developmental Regulation of Effector and Resident Memory T Cell Generation during Pediatric Viral Respiratory Tract Infection. J Immunol 201:432-439
Billing, David; Horiguchi, Michiko; Wu-Baer, Foon et al. (2018) The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection. Mol Cell 72:127-139.e8

Showing the most recent 10 out of 331 publications